Hofmann-Lehmann R, Vlasak J, Rasmussen R A, Jiang S, Li P L, Baba T W, Montefiori D C, Bernacky B J, Rizvi T A, Schmidt R, Hill L R, Keeling M E, Katinger H, Stiegler G, Cavacini L A, Posner M R, Ruprecht R M
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115-6084, USA.
J Med Primatol. 2002 Jun;31(3):109-19. doi: 10.1034/j.1600-0684.2002.01014.x.
Simian-human immunodeficiency viruses (SHIV) allow the evaluation of antiviral strategies that target the envelope glycoproteins of the human immunodeficiency virus 1 (HIV-1) in macaques. We previously protected neonates from oral challenge with cell-free SHIV-vpu+ by passive immunization with synergistic human neutralizing monoclonal antibodies (mAbs) (Baba et al., Nat Med 6:200-206, 2000). mAbs were administered prenatally to pregnant dams and postnatally to the neonates. Here, we used solely postnatal or postexposure mAb treatment, thus significantly reducing the amount of mAbs necessary. All neonatal monkeys were also protected with these abbreviated mAb regimens. Our results are directly relevant for humans because we used mAbs that target HIV-1 envelope glycoproteins. Thus, the large-scale use of passive immunization with neutralizing mAbs may be feasible in human neonates. The mAbs, being natural human proteins, can be expected to have low toxicity. Passive immunization has promise to prevent intrapartum as well as milk-borne virus transmission from HIV-1-infected women to their infants.
猿猴 - 人类免疫缺陷病毒（SHIV）可用于评估针对人类免疫缺陷病毒1型（HIV - 1）包膜糖蛋白的抗病毒策略。我们之前通过用协同作用的人类中和单克隆抗体（mAb）进行被动免疫，保护新生猕猴免受无细胞SHIV - vpu +的口服攻击（Baba等人，《自然医学》6:200 - 206，2000）。单克隆抗体在产前给予怀孕的母猴，产后给予新生猕猴。在此，我们仅使用产后或暴露后单克隆抗体治疗，从而显著减少所需单克隆抗体的用量。所有新生猕猴也都通过这些简化的单克隆抗体制剂得到了保护。我们的结果与人类直接相关，因为我们使用的是针对HIV - 1包膜糖蛋白的单克隆抗体。因此，用中和单克隆抗体进行被动免疫的大规模应用在人类新生儿中可能是可行的。这些单克隆抗体作为天然人类蛋白质，预计毒性较低。被动免疫有望预防HIV - 1感染女性在分娩期间以及通过母乳将病毒传播给其婴儿。
